SCHEMBL21268787

SCHEMBL21268787

Cc1ccccc1N1CCN(c2ccc3ccn(CCO)c3n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.42
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ ATM Q13315 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ ADRB1 P08588 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR1A P08908 1/20 0.37
▸ HTR1D P28221 1/20 0.37
▸ HTR1B P28222 1/20 0.37
▸ HTR3E A5X5Y0 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HTR3B O95264 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ HTR3A P46098 1/20 0.37
▸ HTR3D Q70Z44 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21285495 0.88 PARP1 (0.42) PARP1NPC1RAB9AATMKMT2A
SCHEMBL21281500 0.86 ADRA1A (0.45) PARP1ATMHTR7HTR1AHTR1B
SCHEMBL21273954 0.85 PARP1 (0.45) PARP1ATMALDH1A1HTR7HTR1A
SCHEMBL21273937 0.83 ADRA1A (0.37) PARP1NPC1RAB9AATMKMT2A
SCHEMBL21281585 0.82 PARP1 (0.44) PARP1NPC1RAB9AATMKMT2A
SCHEMBL21268761 0.81 NPC1 (0.35) PARP1NPC1RAB9AATMALDH1A1
SCHEMBL21281450 0.81 HRH3 (0.42) HRH3SLC18A3
SCHEMBL21274100 0.81 HRH3 (0.42) HRH3SLC18A3
SCHEMBL21268806 0.81 HRH3 (0.42) HRH3SLC18A3
SCHEMBL21274058 0.81 SLC18A3 (0.36) PARP1NPC1RAB9AATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives EVOTEC (UK) LTD (GB) 2020-12-24 — — US disclosed
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives EVOTEC (UK) LTD (GB) 2020-12-24 — — US disclosed
CN-112105357-A Pharmaceutically acceptable 6,5 heterobicyclic derivatives UCB生物制药有限责任公司 2020-12-18 — — CN disclosed
WO-2019158731-A1 PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-08-22 — — WO disclosed
EP-3527209-A1 PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES UCB Biopharma SPRL (BE) 2019-08-21 — — EP disclosed
EP-3527209-A1 PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES UCB Biopharma SPRL (BE) 2019-08-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399268-A1 Pharmaceutical 6,5 Heterobicyclic Ring Derivatives STING1, IRF3, NFATC1 PARP1 158/4885NPC1 533/4885RAB9A 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback